May 16, 2023 / 02:30PM GMT
Unidentified Analyst
Good morning, everybody, and thanks for joining day two of the JMP Life Science Conference. My name is John Walden. I'm pleased to have the team from Madrigal Pharmaceuticals joining us Rebecca Taub, CMO; CEO, Paul Friedman; and Chief Commercial Officer, Remy Sukhija. Thanks for joining us today, guys. I think everybody is familiar with the Madrigal story by now and the unmet need in NASH. But maybe to start, can we talk about the master of NASH data and the key learnings and then what that means moving forward for you guys?
Rebecca Taub - Madrigal Pharmaceuticals, Inc. - Director, Founder, Chief Medical Officer and President of Research & Development
Yeah. So as you know, we announced data the December of 42, and we have an update in January of 23 where we achieve both liver biopsy primary endpoints of the study, which was it's a 54-month study in overall, but there was a 52-week serial liver biopsy endpoint and about 1,000 patients. And we showed that resmetirom had both daily doses, 80 and 100 milligrams achieved the primary endpoints which
Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot